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Abstract
Background: The prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among elderly have not
been well described. Our aim was to assess the prevalence, risk factors and mortality of NAFLD in individuals older
than 60 years.
Methods: The data from the Third National Health and Nutrition Examination Survey with linked mortality files
were utilized. NAFLD was defined by United States Fatty Liver Index in the absence of other causes of liver disease.
Cox proportional hazards models were used to assess all-cause and cardiovascular (CV) mortality. All analyses were
performed using SAS software.
Results: Three thousand two hundred seventy-one NHANES-III participants were included. The prevalence rates
from NAFLD were 40.3% (95% CI: 37.2–43.5%) and 39.2% (95% CI: 34.4–44.0%) among 60–74 and > 74 years old.
Among aged 60–74, the risks for 5-year and 10-year all-cause mortality were associated with presence of NAFLD
[adjusted hazard ratios: 1.60 (95% CI: 1.24–1.96) for 5-year and 1.22 (95%CI: 1.01–1.49) for 10-year]. CV mortality were
higher in this group were (aHR: 2.12 (95% CI: 1.20–3.75) for 5-year and 1.06 (95%CI: 0.73–1.52) for 10-year]. In
contrast, in individuals > 74 years old, diagnosis of NAFLD was not associated with all-cause or CVD mortality.
Conclusions: NAFLD is common among elderly population. Although NAFLD is associated with increased risk of
mortality for 60–74-year-old individuals, this risk was not increased in those older than 74 years.
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Background
Non-alcoholic fatty liver disease (NAFLD) is highly preva-
lent in the general population worldwide [1, 2]. Most indi-
viduals with NAFLD have components of metabolic
syndrome (MS) such as type 2 diabetes (T2D), dyslipid-
emia, hypertension and visceral obesity [3–8]. Addition-
ally, NAFLD seems to be more common in Hispanics and
less common in African Americans [9–11]. Although
gender-specific differences in the prevalence of NAFLD
have been debated, increasing age does seem to have an
influence by increasing the prevalence of NAFLD [1, 12,
13]. However, the age cut-off chosen for the definition of
“elderly” may vary across the studies, yielding conflicting
results. In fact, while most studies reported an increased
prevalence and severity of NAFLD in subjects older than
60 or 65 years[14], NAFLD appear to be a common but
benign finding in an octogenarian population with a
prevalence rate of 46.2% [15]. In fact, the prevalence of
MS and co-morbidities in this group with NAFLD does
not seem to be increased as compared to their counterpart
without NAFLD [15]. Conversely, NAFLD patients youn-
ger than 70 years had a significantly higher prevalence of
glucose intolerance, obesity and MS compared with the
elderly patients with NAFLD [15]. In the Rotterdam study,
the prevalence of NAFLD was lower with advancing age,
ranging from 35.8% of participants < 70 years to 21.1% of
participants aged ⩾85 years. Similarly, the association be-
tween number of MS criteria and probability of NAFLD
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weakened with advancing age [16], suggesting other
mechanisms underlying the increased hepatic fat accumu-
lation. Age-related anatomical and functional changes in
the liver can also impact the progression and outcomes of
liver disease [17]. In fact, older individuals lose nearly one
third of their hepatic volume and perfusion, which may
negatively affect the regenerative capacity of the liver [17].
In addition to the age-related lipid accumulation in
non-adipose tissue, including liver, older age is also associ-
ated with sarcopenia, i.e. decreased muscle mass and func-
tion, along with dysregulation of the free radical
scavenging systems which can lead to an increase in the
oxidative stress potentially promoting the progression of
NAFLD [18].
The higher prevalence and higher potential for pro-
gression of NAFLD, which can be associated with older
age, has important implications for burden of disease. In
this context, the growing burden of obesity and T2D in
the United States [19] is exacerbated by the ageing of
the general population [20, 21]. These two parallel tra-
jectories have prompted important questions about the
prevalence and outcomes of NAFLD in the elderly popu-
lation. Therefore, the aim of this study was to assess the
prevalence and long-term outcomes of NAFLD in the
US population over age 60.
Methods
This study represents an analysis of the third National
Health and Nutrition Examination Survey (NHANES III)
conducted by the National Center for Health Statistics
(NCHS) between 1988 and 1994 [22] with the public-use
linked mortality file [23]. NHANES is based on a stratified,
clustered, and multistage probability sample design to
obtain a representative sample of the non-institutionalized
civilian U.S. population. Selected individuals participated in
a home interview and also in a subsequent standardized
physical examination including blood and urine collection
at a mobile examination center (MEC).
Of 19,172 adults in NHANES III, 17,367 (90.6%) at-
tend an examination at a mobile examination center.
We excluded 10,784 young adults aged less than 60
years; 77 who had positive for serum hepatitis B surface
antigen or hepatitis C antibody; 26 who had alcohol liver
disease; 114 who had a transferrin saturation < 50%; 178
with significant alcohol consumption (≥ 20 g per day in
men and ≥ 10 g per day in women). We also excluded
2917 elders with missing data on one or more compo-
nents of US FLI score, leaving a study population of
3271 elders (1434 NAFLD vs. 1837 No NAFLD). Demo-
graphic characteristics and health-related behaviors, and
history of comorbidities did not differ between subjects
included and excluded (Additional file 1: Table S2).
General demographic characteristics collected from
self-reported information included age (years), race/
ethnicity (non-Hispanic white, non-Hispanic black,
Mexican American, or Other race which included other
Hispanic, Asian, and Native Americans), sex, and
current smoker were collected from self-reported infor-
mation. Serum was tested for albumin (g/dL), alanine
aminotransferase (ALT, U/L), aspartate aminotransferase
(AST, U/L), transferrin saturation (%), platelet count
(1000 cell/uL), gamma-glutamyl transpeptidase (GGT,
U/L), creatinine (mg/dL), fasting glucose (g/dL), fasting
insulin (uU/mL), triglycerides (mg/dL), total cholesterol
(mg/dL), high density lipoprotein (HDL, mg/dL), and
low density lipoprotein (LDL, mg/dL).
Definition of liver disease and comorbidities
For NHANES III, abdominal ultrasounds were only per-
formed among participants ages 20–74 [24]. For the pur-
pose of this study, the United States Fatty Liver Index
(US-FLI) as a non-invasive estimate of hepatic steatosis
was used to diagnose NAFLD. Recently, the US FLI have
been validated in the multiethnic U.S. population with
the ability to predict hepatic steatosis [25]. In this study,
participants were presumed to have NAFLD, if they had
a US FLI score of ≥30 in the absence of any other pos-
sible causes of chronic liver disease as described in the
previous paragraphs. As a validation of US FLI, demo-
graphic and clinical parameters of adults aged 60–74
years with any degree (mild to severe) of steatosis on ab-
dominal ultrasounds were compared with those with no
hepatic steatosis (Additional file 1: Table S1). The results
have great affinity with those of adults aged 60–74 years
using US FLI.
Obesity was defined as individuals with BMI ≥ 30 kg/m2.
T2D was defined as having a fasting glucose measure of >
126mg/dL, self-reported medical history of diabetes, oral
hypoglycemic, or insulin use [26]. Hypertension (HTN) was
defined as having systolic blood pressure of > 140mmHg or
diastolic blood pressure of > 90mmHg from an average
three measurements or history of high blood pressure or
history of oral antihypertensive medications. Hyperlipid-
emia (HL) was defined as a serum cholesterol level of ≥200
mg/dL, LDL of ≥130mg/dL, and HDL ≤ 40mg/dL in men
or ≤ 50mg/dL in women. Metabolic Syndrome (MS) was
defined as having at least three of the following [27]: waist
circumference > 102 cm in men or > 88 cm in women, fast-
ing plasma glucose > 110mg/dl, blood pressure > 130/85
mmHg, elevated triglycerides > 150mg/dl, and HDL ≤ 40
mg/dL in men or ≤ 50mg/dL in women. A homeostasis of
model assessment score (HOMA) was calculated using the
equation: fasting glucose (mg/dL) × fasting insulin (uU/
mL)/22.7 [28]. Glomerular filtration rate (GFR) was esti-
mated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation for standardized creatin-
ine [29–32]. Chronic kidney disease (CKD) was defined by
either Urinary albumin-to-creatinine ratio (UACR) ≥ 30
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mg/g or an estimated GFR of ≤60mL/min/1.73m2. The
atherosclerotic cardiovascular disease (ASCVD) risk score
was calculated from each participant’s age, race, sex, smok-
ing status, presence of diabetes, systolic blood pressure, an-
tihypertensive medication, serum cholesterol and high
density lipoprotein levels [33]. NAFLD fibrosis score (NFS)
[34] and aspartate aminotransferase-to-platelet ratio index
(APRI) [35], serum markers of fibrosis, were calculated ac-
cording to the published formulas. History of cardiovascu-
lar disease (CVD) was defined by self-reported medical
history of congestive heart failure, heart attack, or stroke.
History of cancer was also defined by self-reported medical
history of any cancer.
Follow-up mortality data
The NHANES III public linked mortality file provides
follow-up data on vital status from the date of NHANES III
survey participation (1988–1994) through December 31,
2011 or the date of death. Mortality ascertainment is based
on linking NHANES III participants with National Death
Index (NDI) records through a probabilistic match [36].
Participants who were not met any death records were pre-
sumed alive through the follow-up period. Cause of death
was attributed by NCHS based on the international Classifi-
cation of Disease, 9th or 10th revision. Outcomes for this
analysis consisted of all-cause and CVD mortality (ICD-10:
I00-I09, I11, I13, I20-I25, and I60-I69) [23].
Statistical analysis
Examination sample weights, accounting for non-response,
non-coverage, and unequal selection probabilities for cer-
tain categories of the population, were incorporated in order
to produce national estimates. The standard errors of esti-
mates were estimated using Taylor series linearization, a
design-based method [37]. Various socio-demographic and
clinical parameters among elders (≥ 60 years old) compared
by NAFLD status by using Rao-Scott chi-square for categor-
ical variables or Wald test for continuous variables [38, 39].
To assess the effects of NAFLD on mortality out-
comes, Cox proportional hazards models were utilized
by adjusting demographic, metabolic syndrome, and
selected comorbidities. The proportional hazards as-
sumption of the Cox models was examined by testing
time-dependent covariates [40], which showed no sig-
nificant departure from proportionality over time. All
analyses were performed with SAS software, version 9.4
(SAS Institute, Cary, NC) using “SURVEY” procedure,
which incorporate the sample design. Statistical tests
were considered significant at p < 0.05 (two tails).
Results
Baseline characteristics
Among 3271 NHANES subjects 60 years or older with-
out any other causes of liver disease or excessive alcohol
consumption (mean age 71.2 years, 42.1% male, 84.2%
non-Hispanic white and 8.2% non-Hispanic black), the
prevalence of NAFLD was 40.0% (95% CI: 37.5 to
42.4%). Of these, 16.0% had DM, 59.0% had HTN, 18.3%
had CVD, 22.5% had MS, and 15.0% were current
smokers (Table 1).
Baseline characteristics according to NAFLD status,
stratified by age group
Among 2095 elders aged 60 to 74 years without any
other possible cause of liver disease and excessive alco-
hol consumption, the prevalence of NAFLD was 40.3%
(95% CI: 37.2 to 43.5%). Compared to non-NAFLD con-
trols, NAFLD subjects in this age group were more likely
to be male, Mexican American and more likely to have
T2D, HL, HTN, MS, CVD, and had higher measure-
ments for waist circumference, BMI, AST, ALT, ASCVD,
HOMA, NFS, and APRI scores as well as lower eGFR
(Tables 1 and 2). Except for fibrosis markers (APRI and
NFS), which were higher in NAFLD subjects aged > 75,
other characteristics of the two age subgroups were
similar (Tables 1 and 2). Similar findings resulted from
the validation study of using abdominal ultrasounds.
The prevalence of NAFLD among adults aged 60 to 74
years was 40.7% (95% CI: 38.1 to 43.2%). However, HL
and eGFR were no longer significantly different between
adults aged 60 to 74 years with any degree of steatosis
(mild to severe) and those with no hepatic steatosis
(Additional file 1: Table S1).
Long-term outcomes of NAFLD in the elderly subjects
Median follow-up time for the study cohort aged ≥ 60
was 12.3 years (interquartile range, 6.67–18). During this
period of follow up, cumulative mortality was 68.64%
(2380 deaths) from all-cause and 22.71% (824 deaths)
from CVD at 23 years of follow-up.
In the age cohort of 60–74, the median follow-up time
was 16.5 years (interquartile range, 9.8–18.8). NAFLD
subjects were more likely to die than non-NAFLD sub-
jects (66.2% vs 54.0% from all-cause, 20.5% vs 15.7%
from CVD, p < .01). After adjusting for age, male gender,
race, smoking status, presence of metabolic syndrome,
and other selected comorbidities, NAFLD had a 60% in-
crease in the 5-year all-cause mortality (aHR = 1.60, 95%
CI: 1.24–1.96), a 22% increase in the 10-year all-cause
mortality (aHR = 1.22, 95% CI: 1.01–1.49), and a 23% in-
crease in the cumulative all-cause mortality (aHR = 1.23,
95% CI: 1.07–1.42) as compared to non-NAFLD con-
trols. Beside NAFLD, other predictors of all-cause mor-
tality were: male sex, being smoker, hypertension,
advance fibrosis (NFS > 0.676), history of CVD and can-
cer. Since age, race/ethnicity, and diabetes were compo-
nents of US FLI and NFS scores, they were not
considered in multivariable models (Table 4).
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Although NAFLD was significantly associated with an
increased risk of 5-year CVD mortality (aHR = 2.12, 95%
CI: 1.20–3.75), it was not significantly associated with
increased 10-year (aHR = 1.06, 95% CI: 0.73–1.52) and
cumulative CVD mortality (aHR = 1.20, 95% CI: 0.95–
1.52) (Table 3). Other predictors of CVD mortality were:
being smoker, hypertension, hyperlipidemia, history of
CVD and cancer (Table 4). In the group older than 75,
median follow-up time was 7.5 years (interquartile range,
4.08–11.71). In this age group, presence of NAFLD had
no impact on the cumulative all-cause (aHR = 1.12,
95%CI: 0.97–1.29) and CVD (aHR = 1.07, 95% CI: 0.90–
1.26) mortalities (Table 3).
Independent predictors of all-cause mortality were
older age, male sex, being smoker, diabetes, history of
caner and CVD among NAFLD subjects aged 60–74,
whereas older age, male, hyperlipidemia, and advanced
fibrosis among NAFLD subjects aged 75 and over. On
the other hand, older age, being smoker, diabetes, and
history of CVD was associated with increased risk for
CVD mortality among NAFLD subjects aged 60–74,
whereas older age, hyperlipidemia, and history of CVD
among NAFLD subjects aged 75 and over (Additional
file 1: Table S3).
Discussion
In this study, we provide data on the prevalence and the
long-term outcomes of NAFLD among the elderly popu-
lation in the United States. Our results indicate that
NAFLD is highly prevalent in the elderly and, as ex-
pected, is closely associated with components of meta-
bolic syndrome. In this context, there were no
significant differences in the prevalence and risk factors
of NAFLD among the age subgroup (60–74 vs. > 75
years old). These results are consistent with previously
published data [16, 41, 42].
As described above, we have utilized US FLI as a non-
invasive diagnostic method for NAFLD. For our study
population, NHANES III database included ultrasound
data for participants aged between 65 and 74. In this
context, the prevalence of NAFLD was 40.7% by ultra-
sound and 40.3% by US FLI, which suggests that it is a
reliable method for noninvasive diagnosis of NAFLD.
Previous data have also suggested that NAFLD may be
observed more frequently in younger age in males than
females [43]. In contrast, the increase in the prevalence
of NAFLD in women may lag for about a decade, most
likely due to estrogen changes in the post-menopausal
state [18]. In fact, our results suggest that among age
Table 1 Characteristics of NHANES III Participants Aged 60 and over by NAFLD status, U.S. 1988–1994
Aged 60–74 (n = 2095) Aged 75 and over (n = 1176) All (n = 3271)
N. of NAFLD 973 461 1434
% of NAFLD (95% CI) 40.3% (37.2 to 43.5%) 39.2% (34.4 to 44.0%) 40.0% (37.5 to 42.4%)
NAFLD No NAFLD NAFLD No NAFLD
Age, mean (SE) 67.15 (0.12)† 67.33 (0.17) 80.59 (0.23)* 81.22 (0.18) 71.16 (0.18)
Male, % 52.33 (1.74)*† 39.23 (1.39) 43.78 (2.06)* 30.82 (1.40) 42.06 (0.63)
Race, %
non-Hispanic white 81.29 (2.17)† 82.82 (1.27) 89.52 (2.16) 88.80 (1.18) 84.16 (1.38)
non-Hispanic black 7.00 (0.66)*† 9.89 (0.89) 4.56 (0.87)* 8.35 (0.86) 8.20 (0.67)
Mexican American 4.35 (0.45)*† 1.26 (0.12) 1.89 (0.36)* 0.78 (0.14) 2.14 (0.18)
Other race 7.35 (1.94) 6.03 (0.98) 4.02 (1.90) 2.06 (0.53) 5.50 (1.12)
Current Smoker, % 14.85 (1.80)*† 19.94 (0.95) 7.24 (1.07) 8.23 (0.96) 15.02 (0.70)
Waist circumference (cm), mean (SE) 106.86 (0.30)*† 91.22 (0.34) 101.22 (0.55)* 90.65 (0.32) 96.75 (0.25)
BMI, mean (SE) 30.57 (0.19)*† 25.34 (0.12) 28.25 (0.22)* 24.67 (0.11) 27.06 (0.11)
BMI (kg/m2) > 30, % 46.24 (1.78)*† 13.24 (0.75) 31.77 (2.52)* 10.00 (0.86) 24.26 (0.82)
Diabetes, % 33.22 (2.18)* 4.06 (0.58) 32.85 (1.77)* 6.06 (0.76) 16.03 (0.73)
Hyperlipidemia, % 88.12 (1.19)* 81.38 (1.24) 86.07 (1.20)* 79.15 (1.51) 83.46 (0.70)
Hypertension, % 63.32 (1.63)*† 47.53 (1.41) 72.56 (2.02) 71.31 (1.64) 59.00 (0.86)
Metabolic Syndrome, % 44.42 (2.26)* 8.26 (0.62) 40.75 (2.21)* 9.30 (1.04) 22.49 (0.79)
History of cancer, % 17.42 (1.39)† 18.50 (1.52) 27.28 (1.87) 27.11 (1.38) 20.66 (0.99)
History of CVD, % 20.63 (1.28)*† 12.75 (1.14) 31.21 (2.35)* 19.86 (1.54) 18.32 (0.84)
NAFLD was defined as a US FLI score of ≥ 30 in the absence of any other cause of chronic liver disease
*Different from No NAFLD in the same age group (p < .05)
†Different from NAFLD Aged 75 and over (p < .05)
Abbreviation: SE standard error
Data displayed by weighted percentage/mean (SE)
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Table 3 All-cause and cardiovascular mortality among U.S. Elders, NHANES III (1988–1994)
Mortality outcome by
age group
No. of
subjects
No. of
deaths
Cumulative
mortality (%)
5-year Mortality aHR
(95% CI)
10-year Mortality aHR
(95% CI)
Cumulative mortality aHR
(95% CI)
All-cause
Aged 60–74
No NAFLD 1122 643 54.02 Reference Reference Reference
NAFLD 973 625 66.23* 1.60 (1.24–1.96)† 1.22 (1.01–1.49)† 1.23 (1.07–1.42)†
Aged 75 + 1112
No NAFLD 715 675 92.21 Reference Reference Reference
NAFLD 461 437 94.20 1.11 (0.88–1.40) 1.17 (0.99–1.36) 1.12 (0.97–1.29)
Cardiovascular disease
Aged 60–74
No NAFLD 917 201 15.71 Reference Reference Reference
NAFLD 772 188 20.46* 2.12 (1.20–3.75)† 1.06 (0.73–1.52) 1.20 (0.95–1.52)
Aged 75 +
No NAFLD 707 260 34.96 Reference Reference Reference
NAFLD 458 175 36.36 1.05 (0.76–1.44) 1.13 (0.89–1.42) 1.07 (0.90–1.26)
NAFLD was defined as a US FLI score of ≥ 30 in the absence of any other cause of chronic liver disease
Multivariate models were adjusted for male, current smoker, hypertension, hyperlipidemia, advance fibrosis (NFS > .676), and history of CVD and cancer. Age, race,
diabetes were not considered because of components of US FLI score
*Significantly different from No NAFLD (p < .05)
†p < .05
abbreviation: CI confidence interval, aHR adjusted Hazard Ratios
Table 2 Clinical parameters of NHANES III Participants Aged 60 and over by NAFLD status, U.S. 1988–1994
Aged 60–74 (n = 2095) Aged 75 and over (n = 1176) All (n = 3271)
NAFLD No NAFLD NAFLD No NAFLD
AST (IU/L), mean (SE) 21.75 (0.27)* 19.98 (0.17) 21.28 (0.47) 20.51 (0.17) 20.73 (0.13)
ALT (IU/L), mean (SE) 17.83 (0.39)*† 12.43 (0.25) 14.26 (0.61)* 10.68 (0.20) 13.89 (0.29)
Albumin (g/dL), mean (SE) 4.04 (0.02) 4.02 (0.02) 3.99 (0.01) 3.98 (0.01) 4.02 (0.01)
Platelet (1000 cell/uL), mean (SE) 259.01 (3.75) 261.57 (2.90) 252.90 (2.84) 247.93 (3.39) 257.51 (2.23)
ASCVD, mean (SE) 20.80 (0.32)*† 14.42 (0.26) 44.39 (0.63)* 40.95 (0.66) 24.21 (0.42)
eGFR, mean (SE) 76.20 (0.38)*† 78.40 (0.48) 61.34 (0.96)* 65.79 (0.70) 73.67 (0.33)
HOMA, mean (SE) 7.36 (0.36)* 1.79 (0.03) 7.24 (0.57)* 1.80 (0.02) 4.01 (0.14)
NFS, mean (SE) −0.64 (0.06)*† −1.06 (0.05) 0.07 (0.06) −0.05 (0.05) −0.64 (0.04)
NFS, %
> 0.676 13.92 (1.08)*† 6.13 (0.80) 31.54 (2.05)* 23.49 (1.21) 14.20 (0.84)
0.676 - -1.455 60.65 (1.86) 59.50 (1.29) 60.27 (2.14)* 65.78 (1.73) 61.00 (0.88)
< −1.455 25.43 (2.07)*† 34.38 (1.47) 8.19 (1.11) 10.74 (1.20) 24.80 (1.01)
APRI, mean (SE) 0.28 (0.01)* 0.25 (0.00) 0.28 (0.01) 0.27 (0.00) 0.27 (0.00)
APRI (> 0.7) % 2.05 (0.36)* 0.56 (0.15) 1.77 (0.76) 1.08 (0.25) 1.22 (0.14)
NAFLD was defined as a US FLI score of ≥ 30 in the absence of any other cause of chronic liver disease
*Different from No NAFLD in the same age group (p < .05)
†Different from NAFLD Aged 75 and over (p < .05)
Data displayed by weighted percentage/mean (SE)
Abbreviation: CI confidence interval, ASCVD atherosclerotic cardiovascular disease risk score, APRI aspartate aminotransferase to platelet ratio index, FIB-4 fibrosis-4
score, NFS NAFLD fibrosis score, eGFR estimated glomerular filtration rate mL/min/1.73 m2
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60–74 years old, the majority of NAFLD patients were
male. In contrast, for NAFLD subjects older than 75, the
female gender was the majority.
Another interesting aspect of our data is the presence
of severe fibrosis as determined by NAFLD fibrosis
scores in different age groups with NAFLD. In fact, the
proportion of subjects with severe fibrosis (NFS > 0.676)
was higher in both NAFLD subgroups than their
respective controls without NAFLD. Furthermore, the
proportion of NAFLD patients with severe fibrosis
(NFS > 0.676) increased as the NAFLD subjects became
older (60–74 vs. > 75 years old, p < 0.001). This is con-
sistent with the natural history of NAFLD suggesting the
older age is a predictor of advanced fibrosis and adverse
outcomes [44, 45].
The most important aspect of our study was the
long-term mortality outcome of the elderly patients with
NAFLD. For NAFLD group who were between 60 and
74 years old, crude cumulative mortality rates, as well as
adjusted 5-year, 10-year and cumulative mortality risks
were higher than the age matched controls without
NAFLD. Although crude cumulative rates for CV mor-
tality and 5-year adjusted risk for CV mortality were also
high for this age group with NAFLD, 10-year and cumu-
lative CVD mortality risks were not different than the
age matched controls.
In contrast, these mortality rates for the NAFLD group
older than 75 years old were not different than the age
matched controls without NAFLD. These data suggest
that the impact of NAFLD can only be observed up to a
certain age (age 75) after which it is diluted by other
age-related causes of mortality.
To our knowledge, there have been no longitudinal
studies that have examined the epidemiologic and out-
comes assessment of NAFLD in the elderly. The
strength of this study was using population-based data
from NHANES. Although US FLI has been extensively
validated for diagnosing NAFLD, we are not able to
provide more detailed histologic data about the subtypes
of NAFLD in the elderly. Although this type of data
would be valuable, obtaining histologic and outcomes
data from a large population-based cohort is not feasible.
Moreover, in order to detect advanced fibrosis among
patients with NAFLD, we utilized NAFLD Fibrosis
Score, which is a validating scoring system for prediction
of fibrosis. This scoring system includes age as a vari-
able, which might cause a bias when we emphasize the
more advanced fibrosis among elderly, given their ad-
vanced age.
In summary, this in-depth assessment of NAFLD sug-
gests a very high prevalence of NAFLD in the elderly
population in the United States. Although NAFLD is asso-
ciated with increased risk of mortality in those between 60
and 74, the risk is not increased in subject older than 75.
These data should inform clinician and policy makers to
better understand the burden of NAFLD in the ageing
population of the United States [2, 44–48].
Conclusions
Non-alcoholic fatty liver disease (NAFLD) is a growing
global health problem, affecting almost a quarter of the
world’s population. NAFLD is highly prevalent in the
elderly and is closely associated with components of
metabolic syndrome. Although NAFLD is associated
with increased risk of mortality for 60–74-year-old indi-
viduals, this risk was not increased in those older than
74 years.
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Table 4 Independent Predictors of all-cause and CVD morality among U.S. adults aged 60 and over, NHANES III (1988–1994)
All-cause Mortality CVD Mortality
Risk Factors Aged 60–74 Aged 75 and over Aged 60–74 Aged 75 and over
NAFLD 1.23 (1.07–1.42)† 1.12 (0.97–1.29) 1.20 (0.95–1.52) 1.07 (0.90–1.26)
Male 1.41 (1.20–1.65)† 1.55 (1.30–1.84)† 1.50 (1.20–1.87)† 1.51 (1.21–1.87)†
Smoker 2.01 (1.70–2.38)† 1.27 (0.91–1.77) 2.09 (1.61–2.71)† 1.11 (0.66–1.87)
Hypertension 1.45 (1.27–1.67)† 1.23 (1.01–1.51)† 1.60 (1.26–2.03)† 1.24 (0.97–1.60)
Hyperlipidemia 0.96 (0.81–1.13) 1.01 (0.81–1.25) 1.35 (1.01–1.81)† 1.21 (0.88–1.66)
Advanced fibrosis 1.53 (1.21–1.93)† 1.43 (1.25–1.63)† 1.27 (0.88–1.82) 1.37 (1.15–1.64)†
History of CVD 2.00 (1.74–2.31)† 1.17 (0.94–1.46) 3.59 (2.86–4.49)† 1.59 (1.32–1.91)†
History of cancer 1.49 (1.24–1.78)† 1.15 (0.99–1.33) 1.44 (1.08–1.94)† 1.06 (0.90–1.25)
NAFLD was defined as a US FLI score of ≥30 in the absence of any other cause of chronic liver disease
Advance Fibrosis was defined as a NFS of ≥0.676
†p < .05
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